NCT04641247 - A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

November 13, 2026

Study Completion Date

November 13, 2026

Conditions

Ovarian NeoplasmsBreast Neoplasms

Interventions

DRUG

Niraparib

Niraparib tablets or capsules will be given once a day via the oral route.

Trial Locations (25)

1090

RECRUITING

GSK Investigational Site, Vienna

5000

COMPLETED

GSK Investigational Site, Odense C

11042

RECRUITING

GSK Investigational Site, Lake Success

26100

RECRUITING

GSK Investigational Site, Cremona

28040

RECRUITING

GSK Investigational Site, Madrid

28046

RECRUITING

GSK Investigational Site, Madrid

28204

RECRUITING

GSK Investigational Site, Charlotte

30342

RECRUITING

GSK Investigational Site, Atlanta

32224

COMPLETED

GSK Investigational Site, Jacksonville

44195

COMPLETED

GSK Investigational Site, Cleveland

44202

RECRUITING

GSK Investigational Site, Nantes

60426

RECRUITING

GSK Investigational Site, Harvey

85710

COMPLETED

GSK Investigational Site, Tucson

90048

RECRUITING

GSK Investigational Site, Los Angeles

90603

COMPLETED

GSK Investigational Site, Whittier

92024

RECRUITING

GSK Investigational Site, Encinitas

3109601

RECRUITING

GSK Investigational Site, Haifa

02115

RECRUITING

GSK Investigational Site, Boston

60637-1470

RECRUITING

GSK Investigational Site, Grand Rapids

07962-1956

RECRUITING

GSK Investigational Site, Morristown

A-8036

RECRUITING

GSK Investigational Site, Graz

V5Z 4E6

RECRUITING

GSK Investigational Site, Kelowna

M5G 2M9

RECRUITING

GSK Investigational Site, Toronto

H4A 3J1

RECRUITING

GSK Investigational Site, Montreal

06189

COMPLETED

GSK Investigational Site, Nice